Prof. Dr. Alexander C. J. van Akkooi MD, PhDChair of Melanoma Surgical Oncology, Melanoma Institute Australia; Associate Professor of Melanoma Surgical Oncology, The University of Sydney, Sydney, Australia
Prof. Dr. Alexander van Akkooi is a board-certified surgical oncologist specializing in cutaneous oncology (melanoma and non-melanoma skin cancer, particularly Merkel Cell Carcinoma) at the Melanoma Institute Australia, University of Sydney and Royal Prince Alfred Hospital. He is the immediate past-chairman of the EORTC (European Organization for Research and Treatment of Cancer) Melanoma Group. Prof. Dr. van Akkooi has published over 225 peer-reviewed papers (H index 40) in high-impact journals, including NEJM, Lancet, Lancet Oncology, Cell, Nature Medicine, among others, and has presented at numerous international meetings. He is a member of the European Society for Medical Oncology (ESMO), Society for Melanoma Research (SMR), and American Society of Clinical Oncology (ASCO).
Prof. Dr. van Akkooi was awarded his medical degree from Erasmus University in Rotterdam, the Netherlands. He was a resident in general surgery at Maasstad Ziekenhuis in Rotterdam, and underwent residency training in surgical oncology at the Netherlands Cancer Institute in Amsterdam and Erasmus MC Cancer Institute in Rotterdam, the Netherlands. His PhD was awarded cum laude in 2011 from Erasmus University on the topic of "Sentinel Node Tumor Load Assessment in Melanoma: Dilemmas and Clinical Management."
Prof. Dr. van Akkooi is on the Advisory Board of and has received Consultancy Honoraria from Amgen, Bristol-Myers Squibb, MSD-Merck, Merck-Pfizer, Neracare, Novartis, Pierre Fabre, Provectus, Sanofi, Sirius Medical, 4SC. He also reports Research Grants from Amgen and Merck-Pfizer, which were all paid to his institute.
Recent Contributions to PracticeUpdate:
- ESMO 2023: Recommendations From Dr. Alex van Akkooi for Melanoma
- Nivolumab Plus Ipilimumab for Advanced Salivary Gland Cancer
- A Reinforcement Learning Model for AI-Based Decision Support in Skin Cancer
- Ipilimumab With or Without Nivolumab for PD-1 or PD-L1 Blockade–Refractory Metastatic Melanoma
- Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab–Ipilimumab Therapy in Patients With Advanced Melanoma
- Immunotherapy Infusion for Cutaneous Squamous Cell Carcinoma
- mRNA Vaccine and Pembrolizumab Combo Study
- Pembrolizumab in Stage IIB or IIC Melanoma
- Response-Directed Surgery and Adjuvant Therapy in Stage III Melanoma
- ASCO 2023: Abstract Recommendations From Dr. Alexander van Akkooi for Advanced Melanoma